By targeting PSMA on cancer cells with 111In- or 99mTc-labelled PSMA ligands, RGS was successfully introduced for intraoperative use with a γ-probe and acoustic feedback by Maurer et al. [11, 21, 25, 26, 28]. This evidence concerns the gene FOLH1 and cancer.